Standard

Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides. / Desheva, Yulia A.; Leontieva, Galina F.; Kramskaya, Tatiana A.; Smolonogina, Tatiana A.; Grabovskaya, Kornelia B.; Landgraf, Galina O.; Karev, Vadim E.; Suvorov, Alexander N.; Rudenko, Larisa G.

In: Virology: Research and Treatment, Vol. 8, 01.06.2017.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Desheva, Y. A., Leontieva, G. F., Kramskaya, T. A., Smolonogina, T. A., Grabovskaya, K. B., Landgraf, G. O., Karev, V. E., Suvorov, A. N., & Rudenko, L. G. (2017). Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides. Virology: Research and Treatment, 8. https://doi.org/10.1177/1178122X17710949

Vancouver

Author

Desheva, Yulia A. ; Leontieva, Galina F. ; Kramskaya, Tatiana A. ; Smolonogina, Tatiana A. ; Grabovskaya, Kornelia B. ; Landgraf, Galina O. ; Karev, Vadim E. ; Suvorov, Alexander N. ; Rudenko, Larisa G. / Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides. In: Virology: Research and Treatment. 2017 ; Vol. 8.

BibTeX

@article{0ca9ebb5717c478bbf1c206cf9c1a4fe,
title = "Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides",
abstract = "We investigate the protective effect of combined vaccination based on live attenuated influenza vaccine (LAIV) and group B streptococcus (GBS) recombinant polypeptides against potential pandemic H7N9 influenza infection followed by GBS burden. Mice were intranasally immunized using 107 50% egg infectious dose (EID50) of H7N3 LAIV, the mix of the 4 GBS peptides (group B streptococcus vaccine [GBSV]), or combined LAIV + GBSV vaccine. The LAIV raised serum hemagglutination-inhibition antibodies against H7N9 in higher titers than against H7N3. Combined vaccination provided advantageous protection against infections with A/Shanghai/2/2013(H7N9)CDC-RG influenza and serotype II GBS. Combined vaccine significantly improved bacterial clearance from the lungs after infection compared with other vaccine groups. The smallest lung lesions due to combined LAIV + GBSV vaccination were associated with a prevalence of lung interferon-γ messenger RNA expression. Thus, combined viral and bacterial intranasal immunization using H7N3 LAIV and recombinant bacterial polypeptides induced balanced adaptive immune response, providing protection against potential pandemic influenza H7N9 and bacterial complications.",
keywords = "group B streptococcus, intranasal vaccination, Live influenza vaccine, recombinant polypeptides",
author = "Desheva, {Yulia A.} and Leontieva, {Galina F.} and Kramskaya, {Tatiana A.} and Smolonogina, {Tatiana A.} and Grabovskaya, {Kornelia B.} and Landgraf, {Galina O.} and Karev, {Vadim E.} and Suvorov, {Alexander N.} and Rudenko, {Larisa G.}",
year = "2017",
month = jun,
day = "1",
doi = "10.1177/1178122X17710949",
language = "English",
volume = "8",
journal = "Virology: Research and Treatment",
issn = "1178-122X",
publisher = "Libertas Academica Ltd.",

}

RIS

TY - JOUR

T1 - Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides

AU - Desheva, Yulia A.

AU - Leontieva, Galina F.

AU - Kramskaya, Tatiana A.

AU - Smolonogina, Tatiana A.

AU - Grabovskaya, Kornelia B.

AU - Landgraf, Galina O.

AU - Karev, Vadim E.

AU - Suvorov, Alexander N.

AU - Rudenko, Larisa G.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - We investigate the protective effect of combined vaccination based on live attenuated influenza vaccine (LAIV) and group B streptococcus (GBS) recombinant polypeptides against potential pandemic H7N9 influenza infection followed by GBS burden. Mice were intranasally immunized using 107 50% egg infectious dose (EID50) of H7N3 LAIV, the mix of the 4 GBS peptides (group B streptococcus vaccine [GBSV]), or combined LAIV + GBSV vaccine. The LAIV raised serum hemagglutination-inhibition antibodies against H7N9 in higher titers than against H7N3. Combined vaccination provided advantageous protection against infections with A/Shanghai/2/2013(H7N9)CDC-RG influenza and serotype II GBS. Combined vaccine significantly improved bacterial clearance from the lungs after infection compared with other vaccine groups. The smallest lung lesions due to combined LAIV + GBSV vaccination were associated with a prevalence of lung interferon-γ messenger RNA expression. Thus, combined viral and bacterial intranasal immunization using H7N3 LAIV and recombinant bacterial polypeptides induced balanced adaptive immune response, providing protection against potential pandemic influenza H7N9 and bacterial complications.

AB - We investigate the protective effect of combined vaccination based on live attenuated influenza vaccine (LAIV) and group B streptococcus (GBS) recombinant polypeptides against potential pandemic H7N9 influenza infection followed by GBS burden. Mice were intranasally immunized using 107 50% egg infectious dose (EID50) of H7N3 LAIV, the mix of the 4 GBS peptides (group B streptococcus vaccine [GBSV]), or combined LAIV + GBSV vaccine. The LAIV raised serum hemagglutination-inhibition antibodies against H7N9 in higher titers than against H7N3. Combined vaccination provided advantageous protection against infections with A/Shanghai/2/2013(H7N9)CDC-RG influenza and serotype II GBS. Combined vaccine significantly improved bacterial clearance from the lungs after infection compared with other vaccine groups. The smallest lung lesions due to combined LAIV + GBSV vaccination were associated with a prevalence of lung interferon-γ messenger RNA expression. Thus, combined viral and bacterial intranasal immunization using H7N3 LAIV and recombinant bacterial polypeptides induced balanced adaptive immune response, providing protection against potential pandemic influenza H7N9 and bacterial complications.

KW - group B streptococcus

KW - intranasal vaccination

KW - Live influenza vaccine

KW - recombinant polypeptides

UR - http://www.scopus.com/inward/record.url?scp=85044608337&partnerID=8YFLogxK

U2 - 10.1177/1178122X17710949

DO - 10.1177/1178122X17710949

M3 - Article

AN - SCOPUS:85044608337

VL - 8

JO - Virology: Research and Treatment

JF - Virology: Research and Treatment

SN - 1178-122X

ER -

ID: 11494008